Trial Profile
An Multicenter,Phase II Trial of EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Erlotinib; Gefitinib; Icotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Jun 2021 Results (n=60) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 31 Jan 2021 Results (n=57; till Aug 2020) presented at the 2020 World Conference on Lung Cancer
- 02 Nov 2018 New trial record